**Toronto, Ontario — November 25, 2025 — Leads & Copy —** Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a clinical-stage biotechnology company focused on developing life-improving medicines for degenerative muscle diseases, has announced its participation in two upcoming investor conferences.
Satellos will be present at the Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3, 2025, at 12:50 p.m. ET, where they will deliver a presentation. A live webcast of the presentation will be available on the Satellos website, with a replay to follow.
The company will also participate in the Oppenheimer Movers in Rare Disease Summit in New York on Thursday, December 11, 2025, at 1:10 p.m. ET. Satellos will be on a panel discussing polypharmacy in DMD and neuromuscular disease.
Satellos leadership team will be available for one-on-one meetings during both conferences. Investors interested in scheduling a meeting can contact their Piper Sandler or Oppenheimer representatives or reach out to Satellos directly at ir@satellos.com.
Satellos is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Their lead drug candidate, SAT-3247, is an orally administered small molecule designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein identified by Satellos as capable of replacing the dystrophin signal in muscle stem cells. The drug is currently in clinical development as a potential treatment for Duchenne Muscular Dystrophy (DMD).
Satellos is also using its MyoReGenX™ discovery platform to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit.
ir@satellos.com
Source: Satellos Bioscience Inc.
Source: Satellos Bioscience Inc.
